Document is current
Any future updates will be listed below
-
Authors
Santhana Kumar, Karthiga
Brunner, Cyrill
Schuster, Matthias
Kopp, Levi Luca
Gries, Alexandre
Yan, Shen
Jurt, Simon
Moehle, Kerstin
Bruns, Dominique
Grotzer, Michael
Zerbe, Oliver
Schneider, Gisbert
Baumgartner, Martin https://orcid.org/0000-0001-9539-7204
-
Funding
Funding for this research was provided by:
Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (SNF_310030_188793, CRSII5_202245/1, CRSII5_202245/1)
Krebsliga Schweiz (SCL_KLS-3834-02-2016, SCL_KLS-3834-02-2016)
Swiss Cancer Research Foundation (KFS-4853-08-2019)
Childhood Cancer Foundation Switzerland
University of Zurich
- License Information
-
More Information
Article History
Accepted: 19 November 2022
First Online: 10 December 2022
Declarations
:
: Patient material: Not applicable.In vivo PK studies: Housing, experimentation, and animal disposal have been performed in general accordance with the “Guide for the Care and Use of Laboratory Animals: Eighth Edition” (The National Academies Press, Washington, DC, 2011) in the AAALAC-accredited laboratory animal facility.In vivo drug response testing in the AGS/SKOV3 CDX model: The work conducted in animals is in accordance to the German Animal Welfare Act and all procedures were approved by local authorities (Landesamt für Gesundheit und Soziales, LaGeSo Berlin, Germany) under approval number A0010/19 for preclinical sensitivity experiments.
: Not applicable.
: Institution-driven patent applications filed to the European Patent Office for compounds <b>3.14</b> and <b>18.7</b>. In vivo and ADME studies were financed by Invasight AG. KS Kumar is CEO of Invasight AG. MG is a minor pre-seed shareholder of Invasight AG.
